A new trading day began on Tuesday, with Novo Nordisk ADR (NYSE: NVO) stock price down -0.73% from the previous day of trading, before settling in for the closing price of $117.33. NVO’s price has ranged from $92.94 to $148.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 14.25%. Meanwhile, its annual earnings per share averaged 23.72%. With a float of $3.34 billion, this company’s outstanding shares have now reached $3.38 billion.
Considering the fact that the conglomerate employs 63370 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.53%, operating margin of 43.26%, and the pretax margin is 43.77%.
Novo Nordisk ADR (NVO) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Novo Nordisk ADR is 0.02%, while institutional ownership is 10.06%.
Novo Nordisk ADR (NVO) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of 0.73 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.9 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 23.72% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.21% during the next five years compared to 16.48% growth over the previous five years of trading.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Here are Novo Nordisk ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.40. Likewise, its price to free cash flow for the trailing twelve months is 33.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.91, a number that is poised to hit 0.88 in the next quarter and is forecasted to reach 4.23 in one year’s time.
Technical Analysis of Novo Nordisk ADR (NVO)
Compared to the last year’s volume of 4.29 million, its volume of 3.43 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.41%. Additionally, its Average True Range was 2.30.
During the past 100 days, Novo Nordisk ADR’s (NVO) raw stochastic average was set at 7.80%, which indicates a significant decrease from 39.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 16.65% in the past 14 days, which was lower than the 34.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $127.78, while its 200-day Moving Average is $128.03. Nevertheless, the first resistance level for the watch stands at $117.16 in the near term. At $117.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $119.05. If the price goes on to break the first support level at $115.27, it is likely to go to the next support level at $114.07. Now, if the price goes above the second support level, the third support stands at $113.38.
Novo Nordisk ADR (NYSE: NVO) Key Stats
With a market capitalization of 388.83 billion, the company has a total of 4,487,532K Shares Outstanding. Currently, annual sales are 33,724 M while annual income is 12,151 M. The company’s previous quarter sales were 9,821 M while its latest quarter income was 2,893 M.
